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Abstract Head and neck cancer patients are at high risk
for developing second primary tumors. This is known as
Weld cancerization of the aero-digestive tract. In a previous
study, we showed that patients with multiple primary
tumors were more likely to have p53 mutations in histolog-
ically normal mucosae than patients presenting with an iso-
lated tumor. Based on this observation, we postulated that
p53 mutations in normal tissue samples of patients bearing
a single primary tumor could have a clinical value as a bio-
marker for the risk of developing second primary tumors.
Thirty-Wve patients presenting with a single primary tumor
were followed-up for a median of 51 months (range 1
month to 10.9 years) after biopsies of histologically normal
squamous cell mucosa had been analyzed for p53 mutations
with a yeast functional assay at the time of the primary
tumor. During this follow-up, recurrences and non-sterili-
zation of the primary tumor, occurrence of lymph node
metastases, and of second primary tumors were evaluated.
Sixteen (45.7%) patients were found to have p53 mutations
in their normal squamous cell mucosa, and 19 (54.3%)
patients showed no mutation. No relationship was found
between p53 mutations and the occurrence of evaluated
events during follow-up. Notably, the rate of second pri-
mary tumors was not associated with p53 mutations in the
normal squamous mucosa. The correlation between p53
mutations in histologically normal mucosae and the
incidence of second primary tumors is generally low. The
beneWt of analyzing p53 mutations in samples of normal
squamous cell mucosa in every patient with a primary
tumor of the head and neck is doubtful.
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Introduction
Squamous cell carcinoma of the head and neck (SCCHN) is
a very common malignancy and has one of the lowest 5-
year survival rates among all cancers [1]. Although new
surgical techniques, improved radiotherapy regimens and
use of concomitant chemotherapy all improve loco-regional
control, improvement of survival has not been achieved
over the last decades [2]. One of the main reasons for this
lack of eYcacy seems to be that, apart from failure of loco-
regional disease control, head and neck cancer patients are
at high risk of developing second primary tumors (SPT),
regardless of initial treatment modality [3]. This high inci-
dence of SPT reXects the so-called Weld cancerization pro-
cess of the aero-digestive tract, in which the epithelium has
been preconditioned by long-term exposure to carcinogens
[4]. Multifocal disease has been seen in 3–7% of the cases
worldwide [5], and some specialized centers report up to
24% of patients developing metachronous second primary
tumors [6]. One of the major molecular mechanisms of
tumor development lies in multiple mutations in oncogenes
and tumor suppressor genes [7]. Mutation of the tumor sup-
pressor gene p53 is one of the most frequent and it occurs in
about half of all types of tumors [8].
Ten years ago (during the years 1995–1996) we ana-
lyzed multiple biopsies of squamous cell carcinomas and
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548 Eur Arch Otorhinolaryngol (2009) 266:547–551of histologically normal mucosae in 36 patients bearing a
single primary tumor and 16 patients presenting with mul-
tiple synchronous primary tumors. Several biopsies from
the mucosa of the upper aero-digestive tract were taken
from every patient of each group, 117 biopsies from the
36 patients with a primary single tumor and 50 biopsies
from the 16 patients with multiple tumors. A yeast p53
functional assay, a biological assay for transactivation of
a reporter gene in yeast was done on each biopsy speci-
men. The ability to activate transcription of target genes is
a critical activity of p53, which is targeted in tumors. In
most cases, failure to activate transcription in tumors
results from mutations in the p53 DNA binding domain,
which lower the aYnity of p53 for DNA. By testing the
biologically important function of the protein, it is possi-
ble to distinguish polymorphisms from tumorigenic muta-
tions, and to identify mutations at many diVerent sites in a
single assay [9]. Using this method, mutations were
detected in 46 of 53 (87%) tumors. Among the biopsies of
histologically normal mucosae taken from the upper aero-
digestive tract, p53 mutations were identiWed in 38 of 50
(76%) biopsies from patients presenting with multiple
tumors, compared with 38 of 117 (32%) biopsies from
patients presenting with a single tumor (P < 0.000001).
All 16 patients presenting with multiple tumors had at
least one positive biopsy, compared with only 19 of 36
(53%) patients with single tumors (P < 0.001) [10]. These
results conWrmed that inactivation of the p53 tumor sup-
pressor gene is a frequent and early event in the pathogen-
esis of head and neck tumors. Furthermore, expansion of
multiple clones of mutant p53-containing cells was found
to be an important biological mechanism of Weld cancer-
ization. Since patients with multiple primary tumors were
signiWcantly more likely to show p53 mutations in normal
squamous cell mucosa, compared to patients bearing a
single tumor, it was postulated that p53 mutations in nor-
mal squamous cell mucosa could represent a molecular
marker of multifocality [9, 10]. As 25% of the patients
presenting with a single tumor are expected to develop
additional tumors [6], follow-up of these patients is of
great interest, especially if detection of p53 mutations in
adjacent normal squamous mucosa permits to predict a
multifocal pattern of disease. A systematic analysis of p53
mutations in histologically normal tumor-distant mucosae
(¸5 cm from the primary) would thus facilitate identiWca-
tion of those patients most likely to beneWt from intensive
follow-up for the detection of metachronous second pri-
mary tumors.
Here, we present the results of the long-term follow-up
of the above-mentioned 36 patients presenting with a single
primary tumor, who, 10 years ago, had been tested for p53
mutations in their histologically normal squamous cell
mucosae.
Patients and methods
Approval for the study was obtained from the local ethical
committee (protocol F63/94) and informed consent was
obtained from all persons prior to inclusion. From October
1995 to July 1996, 36 unselected patients underwent diag-
nostic broncho-esophagoscopy for a single primary
SCCHN at the University Hospital CHUV, Lausanne, Swit-
zerland. One hundred and seventeen biopsies were taken
during this endoscopy. Three quarters of the biopsies of
histologically normal squamous cell mucosa came from
esophagus and the rest from the buccal mucosa. In 90% of
the cases, the biopsy was cut in two pieces. One half was
sent for conventional histological examination and the sec-
ond half was used for assessing p53 mutation events. All
samples of normal tissue were taken at least 10 cm away
from the primary tumor, and the distance between individ-
ual biopsies was at least 2 cm. Samples for functional test-
ing were placed directly in RNA lysis buVer and
immediately frozen on dry ice, and stored at ¡80°C until
use. Procedure of identiWcation of p53 mutations by yeast
functional assay has been described earlier [9, 10].
The data collected included age, gender, primary tumor
site (oral cavity, pharynx, larynx, esophagus, rhinophar-
ynx), tumor size (T1–4), lymph node status (N0–3), staging
according to the American Joint Committee on Cancer
Stage (stages I–IV), initial therapy (surgery only, radiation-
therapy with or without concomitant chemotherapy, sur-
gery with radiation-therapy with or without concomitant
chemotherapy, palliative treatment), and cause of death.
During the follow-up, recurrences and non-sterilization of
primary tumor, occurrence of lymph node metastases, and
of second primary tumors (SPT) were recorded.
Statistical analysis: major endpoints of this study were
local relapse, second primary tumors (SPT), lymph node
metastases, and death during the follow-up, in relation to
the p53 mutation status in tumor-distant mucosae. Calcula-
tions were performed using Fisher’s exact test for univari-
ate analysis and P < 0.05 was considered as signiWcant. The
Kaplan–Meier method and log-rank test were used to com-
pare overall and disease-related survival curves between
groups with p53 wild type and mutated type. Statistical
analyses were done using the package Survival from the R
Project for statistical Computing (http://www.r-project.org/)
[11, 12].
Results
Thirty-Wve patients with a single primary SCCHN were
included in this study. One patient from the previous study
was excluded because of loss to follow-up directly after
diagnostic broncho-esophagoscopy. The p53 status in the123
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clinical characteristics are summarized in Table 1. Sixteen
out of 35 (45.7%) patients showed p53 mutations in at least
one biopsy of normal tissue, and 19 out of 35 (54.3%)
patients showed no p53 mutation. There was no statistically
signiWcant diVerence between the two groups concerning
age, gender, primary tumor site, stage, and initial treatment.
The follow-up period ranged from less than 1 month to 131
months (10.9 years), with a mean period of 54 months for
the group with p53 mutation, 57 months for the group with-
out mutations. A total of 21 patients died during the follow-
up period. No relationship was found between overall sur-
vival and p53 mutation status (P = 0.213). Five patients in
each group died of tumor-related events. Disease-speciWc
survival did not signiWcantly diVer between the two groups
(P = 0.914). There was no association between disease-free
survival and the p53 mutation status (P = 0.439). The rate
of SPT was not associated with p53 mutation status in sam-
ples of normal mucosa (P = 1) (Table 2). In the group with-
out p53 mutation, 2 of 19 (10.5%) patients developed a
SPT: one patient who presented with a primary retromolar
space tumor developed an SPT on the Xoor of the mouth
after 24 months; the other patient presented with a pulmo-
nary carcinoma 21 months after the treatment of a primary
squamous cell carcinoma of the esophagus. Two of 16
(12.5%) patients with p53 mutation developed broncho-
genic carcinomas as SPT; one patient 97 months after the
treatment of a primary tongue base tumor and the other
patient 14 months after the treatment of a primary tumor
situated on the border of the tongue. There was no statisti-
cally signiWcant diVerence between the two groups in the
incidence of loco-regional recurrence or progression (P = 1).
Discussion
Mutations leading to inactivation of the p53 tumor sup-
pressor gene are a frequent event in the pathogenesis of
head and neck tumors. Genetic analysis of histologically
normal samples of mucosae revealing the presence of
multiple clones of mutant p53-containing cells has formed
the basis for a molecular understanding of the Weld canc-
erization process [10]. According to this observation, we
postulated that the p53 status of normal squamous cell
mucosae samples might be relevant for predicting the
clinical outcome of head and neck patients and could be
used as a biomarker to predict a multifocal pattern of dis-
ease, thus facilitating identiWcation of patients at high risk
of developing SPT.
To assess the clinical value of p53 mutations in normal
tissue, we used a functional assay testing the transcriptional
competence of human p53 expressed in yeast. The results
were compared with the long-term follow-up of the
patients.
Table 1 Distribution of patients according to p53 status in histologi-
cally normal mucosa
P values from univariate analysis with P < 0.05 considered signiWcant
p53 
Mutated
p53 Not 
mutated
P
Overall 16 19
Age 0.26
>65 14 13
·65 2 6
Gender 0.24
Female 2 6
Male 14 13
Anatomic site
Oral cavity 3 5
Pharynx 8 9
Larynx 2 4
Esophagus 2 1
Rhinopharynx 1 0
Staging 0.85
Stage I 1 1
Stage II 2 4
Stage III 3 5
Stage IV 10 9
Tumor size 0.54
T1 2 2
T2 2 6
T3 6 7
T4 6 4
Lymph node 0.35
N0 6 10
N1–3 10 9
Initial therapy
Surgery 4 8
Surgery + radiation § 
chemotherapy
4 3
Radiation § chemotherapy 6 5
Palliative therapy 2 3
Table 2 Outcome of patients according to p53 status in histologically
normal mucosa
p53 
Mutated
p53 
Not mutated
Events during follow-up
Deaths; overall 13 8
Deaths; tumor-related 5 5
SPT 2 2
Loco-regional 
recurrence/progression
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550 Eur Arch Otorhinolaryngol (2009) 266:547–551The incidence of p53 mutation in our study was 45.7%.
In the literature, this incidence varies from 47% to less than
5% [13–15], whereas in several other studies, no p53 muta-
tions were found in normal tissue [16–18]. These variations
in incidence of p53 mutation could partially be explained
by the heterogeneity of the diVerent studies, in terms of the
techniques used for assessing p53 mutations, and of the
localization of tumors.
This study did not demonstrate any relationship between
the p53 mutations of histologically normal tissues distant
from the primary tumors and the clinical outcome.
Although p53 mutations were associated with a slight
decrease in disease-free and overall survival—the number
of overall deaths was 13 in the group with p53 mutations
versus eight patients in the group without p53 mutation—
this diVerence was not statistically signiWcant. This lack of
statistical power may be due to the low number of cases in
our study. Especially, the occurrence of SPT was almost
identical in both groups. In each group, two patients pre-
sented with a SPT, and three of them were located in the
lungs. Consequently, p53 mutations in histologically nor-
mal tissue do not seem to be a reliable prognostic factor of
the clinical outcome of patients.
Homann et al. [15] analyzed the clinical outcome of
head and neck cancer patients in relationship to p53 protein
overexpression assessed by immunohistochemistry in
tumor-distant epithelia. Their results showed no signiWcant
correlation between mucosal p53 overexpression and dis-
ease-free and overall survival. Contrary to our own results,
their series showed a statistically signiWcant association
between p53 overexpression in normal mucosa and the
incidence of SPT. A possible explanation for these contra-
dictory results might be the diVerent mutation detection
techniques used in these two series. Even if immunohisto-
chemical detection of the p53 protein is widely used as a
marker of p53 gene mutation, this technique leads to
discordant results in up to 40% of the cases [19, 20]. Fur-
thermore, correlation between p53 mutations and overex-
pression has been found to be low in tumor-distant mucosa.
The method of yeast p53 functional analysis that we used
allows the screening of the p53 gene (codons 52-364) with
a high sensitivity and speciWcity, but it seems clear from
our results that more complete analysis of the genetic
changes in preneoplastic cells will be needed to identify
useful prognostic biomarkers in SCCHN. Carcinogenesis is
a complex phenomenon with multiple genetic lesions and
gene product interactions, so it is not surprising that a sin-
gle molecular marker cannot predict the prognosis accu-
rately [21]. Indeed, since performing our initial study
microarray techniques have been developed that permit
testing of the entire genome in a single assay. Use of these
techniques would provide a much more comprehensive
view of the extent of genetic damage to the normal mucosa.
Another reason for the lack of correlation between p53
mutations in tumor-distant mucosa and the development of
SPT in our series might be the small number of cases, espe-
cially when considering that SPTs are far more likely to
develop in patients initially presenting with earlier stages of
disease. The ability to identify patients at increased risk of
developing multifocal disease is most important in patients
with small primary tumors (T1 and T2 cancers), because
more than 80% of SPTs are small superWcial tumors (in situ
or T1) which are amenable to non-mutilating surgery [5, 6].
The statistical power of our series was probably diminished
by this property of SCCHN, because more than half of the
patients presented with advanced stages of the disease (III
and IV). Although this study failed to demonstrate any ben-
eWt from the screening of p53 mutations in normal squa-
mous cell mucosae of head and neck cancer patients, p53
mutations might be predictive of SPT and of disease-spe-
ciWc survival in a population presenting with earlier stages
of the disease. Further studies are needed to conWrm this
hypothesis.
Conclusion
Contrary to our initial assumption, this study did not show
any correlation between p53 mutations in histologically
normal squamous cell mucosa of the head and neck and the
incidence of SPT. The latter is generally low and the beneWt
of analyzing p53 mutations in tumor-distant mucosae in
every patient presenting with a primary head and neck can-
cer is doubtful. It is possible that other markers might
improve the clinical value of p53 status and so facilitate
identiWcation of those patients who are at high risk of
developing metachronous second primary tumors.
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